Analysts Set Novavax, Inc. (NASDAQ:NVAX) Price Target at $15.86

Shares of Novavax, Inc. (NASDAQ:NVAX) have been assigned an average rating of “Hold” from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $15.8571.

Several equities analysts have recently issued reports on NVAX shares. B. Riley reiterated a “buy” rating on shares of Novavax in a research report on Monday, May 19th. Citigroup began coverage on Novavax in a research report on Tuesday, June 17th. They set a “sell” rating and a $6.00 price objective for the company. JPMorgan Chase & Co. dropped their target price on Novavax from $9.00 to $7.00 and set an “underweight” rating on the stock in a report on Friday, May 9th. Finally, Bank of America dropped their target price on Novavax from $10.00 to $9.00 and set a “neutral” rating on the stock in a report on Tuesday, July 22nd.

Institutional Investors Weigh In On Novavax

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NVAX. Sanofi bought a new position in shares of Novavax in the fourth quarter valued at $55,319,000. Park West Asset Management LLC acquired a new stake in Novavax during the 1st quarter valued at $16,210,000. Deep Track Capital LP acquired a new stake in Novavax during the 4th quarter valued at $16,080,000. Jupiter Asset Management Ltd. raised its stake in Novavax by 195.9% during the 2nd quarter. Jupiter Asset Management Ltd. now owns 880,410 shares of the biopharmaceutical company’s stock valued at $5,547,000 after purchasing an additional 582,858 shares during the period. Finally, Allianz Asset Management GmbH acquired a new stake in Novavax during the 2nd quarter valued at $3,382,000. Institutional investors own 53.04% of the company’s stock.

Novavax Stock Performance

Shares of NASDAQ NVAX opened at $8.37 on Wednesday. The company has a current ratio of 2.36, a quick ratio of 2.03 and a debt-to-equity ratio of 5.93. The stock has a 50 day simple moving average of $6.98 and a 200-day simple moving average of $7.21. The company has a market cap of $1.36 billion, a PE ratio of 3.67, a P/E/G ratio of 0.11 and a beta of 2.50. Novavax has a 12-month low of $5.01 and a 12-month high of $15.22.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.74. The business had revenue of $239.24 million during the quarter, compared to the consensus estimate of $149.19 million. Novavax had a negative return on equity of 142.33% and a net margin of 39.20%. The business’s revenue was down 42.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.99 earnings per share. On average, equities research analysts forecast that Novavax will post -1.46 EPS for the current year.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.